Investors Alert: Class Action Deadline Looms for Inovio Pharmaceuticals Shareholders

In light of recent developments, Faruqi & Faruqi, LLP, a prominent national securities law firm, is reaching out to investors of Inovio Pharmaceuticals, Inc. to bring attention to a critical deadline regarding a securities class action lawsuit. The firm is investigating potential claims against Inovio, which trades under the ticker symbol INO on NASDAQ.

What You Need to Know

The deadline for shareholders to seek the role of lead plaintiff in a federal securities class action against Inovio is set for April 7, 2026. This class action is meant for individuals who incurred losses exceeding $50,000 in Inovio’s stock between October 10, 2023, and December 26, 2025. If you believe you fall into this category, it’s crucial to examine your legal options immediately.

Faruqi & Faruqi Senior Partner James (Josh) Wilson encourages impacted investors to reach out directly to discuss the situation. This is a significant moment for shareholders, as the outcomes of class actions can greatly influence the future compensations and changes within the company.

The Allegations

The class action complaint suggests that Inovio and its executives may have violated federal securities laws by issuing misleading statements and failing to disclose critical information regarding their manufacturing standards and regulatory plans. The lawsuit alleges that there were several misrepresentations, including:
1. Inovio’s CELLECTRA device manufacturing was inadequate, which could delay critical resubmissions.
2. The expectations regarding the submission of the Biologics License Application (BLA) for INO-3107 to the FDA have been called into question.
3. Insufficient justification for seeking FDA accelerated approval potentially impacted market perceptions and stock prices.

These factors culminated in a significant stock price decline of 24.45% on December 29, 2025, when the FDA indicated that Inovio had not submitted adequate information for an accelerated approval pathway.

What Should Shareholders Do?

Shareholders are retained as crucial participants in this ongoing litigation. If any member of the putative class wishes to become a lead plaintiff, they have the choice to either engage directly through their chosen legal counsel or remain passive. Importantly, your potential recovery will not be affected by whether or not you serve as lead plaintiff.

Faruqi & Faruqi is also encouraging anyone with information regarding Inovio’s operations, including whistleblowers and former employees, to come forward. The firm is committed to building a factual basis for the case and potentially recovering compensation for affected shareholders.

For more detailed information about the case and to learn about your options, potential lead plaintiffs can visit Faruqi & Faruqi's dedicated webpage on Inovio's class action.

As the April 7, 2026 deadline approaches, it is essential for investors to be proactive. For personalized advice or to discuss legal rights, those affected can contact Joe Wilson at Faruqi & Faruqi at 877-247-4292 or at their office directly at 212-983-9330 (Ext. 1310).

Background on Faruqi & Faruqi

Founded in 1995, Faruqi & Faruqi, LLP has established itself as a national leader in securities law, successfully recovering hundreds of millions for investors throughout its history. The firm has gained a reputation for its tenacity in pursuing justice on behalf of shareholders and ensuring corporate accountability. With offices in key cities such as New York, Pennsylvania, California, and Georgia, it is well-positioned to represent investors facing complex issues like those related to Inovio Pharmaceuticals.

In conclusion, Inovio shareholders are advised to stay vigilant about their rights and options in light of the upcoming class action deadline. Whether you choose to act as a lead plaintiff or remain a class member, keeping informed is the first step toward potential recovery.